Paper Details

  1. Home
  2. Paper Details

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time.

Author: FossJ F, KarrisonT, MossJ, O'ConnorM, OsinskiJ, RoizenM F, YuanC S

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Methylnaltrexone, the first peripheral opioid receptor antagonist, has the potential to prevent or reverse the gastrointestinal side effects of opioids. Studies showed that oral methylnaltrexone prevented morphine-induced delays in gastrointestinal transit time.
Paper Details　
Original Abstract of the Article :
Methylnaltrexone is the first peripheral opioid receptor antagonist. It has the potential to prevent or reverse the peripherally mediated gastrointestinal effects of opioids. In previous human volunteer trials, we demonstrated that oral uncoated methylnaltrexone prevented morphine-induced delay in g...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1067/mcp.2000.105037

データ提供：米国国立医学図書館（NLM）

Methylnaltrexone: A New Hope for Opioid-Induced Constipation?

This study delves into the realm of [gastrointestinal pharmacology] and its intricate relationship with opioid medications. They used a [human volunteer trial] to investigate the potential of [enteric-coated methylnaltrexone] to alleviate a common side effect of opioid use: [constipation]. The researchers were particularly interested in [how methylnaltrexone could prevent the delay in oral-cecal transit time] caused by opioids. Their findings suggest that [methylnaltrexone can effectively prevent this delay], offering a glimmer of hope for individuals struggling with opioid-induced constipation.

A Ray of Light for Opioid Users

These findings are quite promising for individuals who rely on opioids for pain management. As the authors point out, [methylnaltrexone] represents the first peripheral opioid receptor antagonist, which means it targets the gastrointestinal tract, leaving the central nervous system effects of opioids intact. This could translate into relief from constipation without compromising pain control.

Staying Hydrated and Taking Things Slowly

While this research offers exciting possibilities, it's important to remember that [opioid-induced constipation] is a complex condition that can be influenced by a variety of factors. Maintaining a healthy lifestyle with adequate hydration and a fiber-rich diet is crucial. If you're experiencing constipation, it's always best to consult with your doctor or a qualified healthcare professional to determine the best course of action.

Dr. Camel's Conclusion

This study, like a shimmering oasis in the vast desert of gastrointestinal research, highlights the potential of methylnaltrexone to improve the lives of individuals struggling with opioid-induced constipation. While further research is needed, this work offers a promising new direction in the search for effective solutions to this common and often frustrating side effect.
Date :
  1. Date Completed 2000-05-18
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

10801249

DOI: Digital Object Identifier

10.1067/mcp.2000.105037

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.